key: cord-0742938-6uh3hkj5
authors: Goyal, Madhusudan; Tewatia, Nisha; Vashisht, Hemlata; Jain, Reena; Kumar, Sudershan
title: Novel Corona Virus (COVID-19); Global Efforts and Effective Investigational Medicines: A Review
date: 2021-05-01
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.04.011
sha: 6ae6d7fa2d4182d5bcfa2643229ddd9b390c76c0
doc_id: 742938
cord_uid: 6uh3hkj5

Coronavirus disease-2019 (COVID-19), associated with the outbreak of deadly virus originating in Wuhan, China, is now a global health emergency and a matter of serious concern. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is rapidly spreading worldwide, and WHO declared the outbreak of this disease a pandemic on March 11, 2020. Though some of the countries have succeeded in slowing down the rate of the spread of this pandemic, most the countries across the globe are still continuing to experience an increasing trend in the growth and spread of this deadly disease. Hence, in the current scenario, is has now become essential to control and finally irradicate this deadly disease using an effective vaccine. One can expect the prominent role of already available antivirals, antibodies and anti-inflammatory drugs in the market, in this pandemic. Immunomodulatory and biological therapeutics are also in the high expectations to combat COVID-19. RNA based vaccines might be more advantageous over traditional vaccines, to deal with the pandemic threat. Aiming towards this direction, clinical trials for SARS-CoV-2 vaccine are currently underway all across the globe. Currently, about 150 health related organizations and research labs are in the progress for the evolution of COVID-19 vaccines, globally. The initial aim of these clinical trials is to assess vaccine’s safety, which is tested in Phase I/II/III studies where the primary outcomes typically examine the frequency of adverse effects. The vaccine is about to undergo phase III testing in several countries such as India, USA, South Africa, Brazil and England. US Government, under Operation Wrap Speed is even ready to sponsor three candidates, namely-The University of Oxford and AstraZeneca’s AZD1222; Moderna’s mRNA-1273; and Pfizer and BioNTech’s BNT162 for Phase III trials.

SARS was the first CoV outbreak that appeared between November 2002 -July 2003 all over the world. It had a mortality rate of 9.6% and 8098 infected cases, 774 deaths were reported in 29 countries [17] . The disease was cured using broad-spectrum antibiotics, as no specific and effective antiviral medication was known. [18] , though a purine nucleoside analogue, Ribavirin, was tried as a broad-spectrum antiviral agent. Antiviral medicament such as lopinavir/ritonavir combination used as Human Immunodeficiency Virus (HIV) protease inhibitor was also tried to treat SARS-CoV as it was reported to have in-vitro antiviral activity [19] .Th erapies included traditional Chinese medicine (TCM), interferons and immunomodulators like pentaglobulin, corticosteroid, convalescent plasma etc. were also found to be useful to treat SARS [20, 21] , though no efficient vaccine was developed. Even after the end of SARS in 2004, various suspected cases have been observed from time to time.

The MERS was another CoV outbreak that appeared between September 2012 and January 2020 all over the globe. It had a mortality rate of 34.4% and 2519 affected authenticated cases, 858 reported death cases in 29 countries globally [22] . Still, no prominent vaccine or treatment for MERS have been developed even after the investigation of several antiviral medicaments [23, 24] . The phenomenal trial to treat MERS-CoV was initiated in July 2016, in which 194 patients participated. In this trial a mixture of interferon-β1b and Lopinavir/ritonavir was used on random basis to test the potency and efficiency of the drug combination on the patients under trial [25] . The results are not at all encouraging, as in the first phase of trial only three efficient vaccine candidates to combat MERS-CoV have been identified. [26] . Moreover, it is very likely that even in near future, no MERS vaccine will be available in the market.

The COVID-19 pandemic outbreak was first recognized at Wuhan, China in December, 2019. It affected both health and economy of the entire world in a very short span of time [27] .

Currently, there are more than 96.2 million substantiate COVID-19 cases with about 2.06 million death reported so far across the world, with a reported the recovered patients 69.8 million from COVID-19 [28] . The data reported is in approximation as there was not efficient testing to report the exact morbidity levels. Moreover, the treatments and therapies to combat the virus, were neither in the order of expectations, nor clinically proven to fight against the viral loads of SARS-CoV-2, making the treatments supportive only. Further, the WHO has not released the treatment guidelines to win over the virus. Several COVID-19 drugs and J o u r n a l P r e -p r o o f medications have been started to develop but everlasting result for the COVID-19 affected patients continue to remain a hope.

For the deterrence and handling of COVID-19, life-saving vaccine or other effective medication has still not been introduced in the market but various health sector agencies like US [29] [30] [31] [32] 

Remdesivir (GS-5734), an antiviral drug for 'EBOLA', has been initially declared to treat COVID-19 patients "under emergency use" by Emergency Use Authorization (EUA) of Food and Drug Administration (FDA), United State of America. Remdesivir has demonstrated mechanism to overcome genetic mutations and drug resistance in coronavirus. It imitates as a fragment of the RNA of the virus and gets added into the strand of RNA during the replication of the virus. Once this happens, further replication of the virus does not take place, leaving the RNA strand incomplete, further making the generation of critical parts of viral RNA impossible [33, 34] . Beigel et al. [35] though have reported the results of the drug trial on Covid-19 patients, highlighting the decrease in the mortality rate and the squatter recovery time but fail to give ant statistical significance.

Favilavir, an oral anti-viral drug has been approved as a treatment for coronavirus by The National Medical Products Administration of China. The drug was originally manufactured by Fujifilm Toyama Chemical Ltd, Japan, for the treatment of influenza. Studies have revealed that favilavir gets activated on getting inside the cell and then finally get incorporated into the RNA of the virus, as the novel coronavirus is an RNA virus. The multiplication of the virus is restricted inside the body of the host, resulting in the reducing viral load inside the host cell. [36] .

In collaboration with the University of Massachusetts Medical School and Massachusetts General Hospital (Brigham and Women's Hospital), the United States' second phase trial will J o u r n a l P r e -p r o o f take up about fifty patients of COVID-19. Experimental data given by Qingxian Cai et.al., [37] for COVID treatment with Favipiravir hasn't been substantiated as a game changers but is defiantly helpful in diminishing the load of the virus.

Ribavirin, an antiviral drug, is frequently used in amalgamation with other drugs for curing the viral hemorrhagic fevers and chronic hepatitis C viral infection (HCV), with the approval of FDA. It is a prodrug which is metabolized into nucleoside analogs which block the viral RNA synthesis and viral mRNA capping [38] . Currently, Ivan Fan-Ngai Hung et. al. [39] have published trial reports that the combination of ribavirin with interferon and/or ritonavir/lopinavi, as a triple combination, is having a potential to combat COVID-19 virus.

Russia, without any major untoward effects. The drug is reported to inhibit virus-associated cytokine dysregulation and pneumonia. This medication has a potential to act therapeutically against various viral and infectious diseases due to its broad-spectrum antiviral characteristics.

Arbidol hinders viral entry into a cell of host's body and stimulates enduring response.

Moreover, it could suppress fusion between the cell membrane of the cell, which has been targeted and the viral capsid, thus averting the entry of the virus [40, 41] . Umifenovir is used alone or in combination with other antiviral medication, in a few COVID-19 clinical studies.

Recently, Zhen Zhu et. al. reported that Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 [42] . Recently, preliminary reports given by Jin-nong Zheng [43] , China, testified that it unveiled compelling anti-COVID-19 characteristics in contrast to the mechanism with IC50 from 10-30 µM. And this is how, arbidol has been appraised for the therapeutic usage in COVID-19 cases. Central Drug Research Institute (CDRI), India, has secured approval for carrying out Phase III trial for the use of Umifenovir in the treatment of Covid-19.

Merimepodib is an Oral antiviral, developed by ViralClear Pharmaceuticals and is in second phase of trial together with remdesivir (ClinicalTrials.gov Identifier: NCT04410354). It's usage to cure COVID-19 patients has even been cleared for trails by US FDA, for the patients who have been hospitalized with COVID-19 and require supplemental oxygen or are on non-invasive ventilation/high flow oxygen devices. Merimepodib acts by controlling the function of inosine-5'-monophosphate dehydrogenase (IMPDH), resulting in attenuation of guanosine that is used at the time of replication by the viral polymerase [44] .

Nitazoxanide Nitazoxanide tablets (NT-300; Romark Laboratories) amalgamated with other antiviral medications obstruct the imitation of a wide range of viruses related to respiratory tracts in cell culture, including SARS-CoV-2 [45] . Two third phase trials for deterrence of are being introduced in high-risk populations, including healthcare workers and elderly residents enduring care facilities. Along with this step, a third trial towards the early medicaments of COVID-19 is intended (ClinicalTrials.gov Identifier: NCT04343248).

The recent report by Caly et al., [46] approved by FDA, describing the antiviral potential of ivermectin against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a potential candidates for COVID-19 treatment. According to the studies by Carlos Chaccour et. al., [47] ivermectin considerably lower down the mortality rates in the patients receiving the drug with intense care.

Niclosamide, an anthelmintic agent, approved by FDA, is capable of showing the antiviral properties [48] . A trademarked formulation that decreases prolonged transmission and infection by targeting the viral pool in the gut has been synthesized. Commencement of a phase 2a or 2b research and study has been scheduled for the mid-2020 (ClinicalTrials.gov Identifier:

Rintatolimod is a broad-spectrum antiviral agent. Roswell Park Cancer Institution in collaboration with AIM ImmunoTech Inc., US. examined Toll-like receptor 3 (TLR-3) agonist as a potential therapy for COVID-19 (ClinicalTrials.gov Identifier: NCT04379518).

Beta-D-N4-hydroxycytidine, a broad-spectrum antiviral drug [49] is bioavailable for oral intakes. It has been examined on SARS-CoV infected mice by both therapeutic and prophylactic administration, and has ended up to show reduced viral titer, a better pulmonary function and body weight loss. Very soon clinical trials on human body will be announced.

Bemcentinib is a selective oral AXL kinase impediment, which has shown to unveil potent antiviral activity against several cloaked viruses, including Zika virus and Ebola virus. A second phase of research and trials of the drug, in hospitalized COVID-19 patients, is premeditated as a part of the UK's "ACCORD" i.e. Accelerating COVID-19 Research and Development inventiveness [50] . Recently, preclinical data suggest that bemcentinib is potentially useful for the treatment of early SARS-CoV-2 infection.

is effective to the nanomolar order [51] Antroquinonol is an anti-inflammatory/antiviral medication which decreasers the viral protein synthesis and viral nucleic acid replication in both animal and cell experiments. It has also been demonstrated, during the treatment of mice with high inflammation, that this drug prevents tissue and organ damage. The antroquinonol drug from Golden Biotech, has been approved by FDA, for a second phase clinical trial on mild-to-moderate COVID-19 pneumoniatic patients (Source: Golden Biotech).

In 2000, Ritonavir and Lopinavir, were approved by FDA. Both belong to a class of drugs and medicines called protease inhibitors, also known to target 3CLpro, a SARS-CoV nonstructural protein. During the SARS-CoV epidemic, the combination of these medications with ribavirin was dealing with the reduction of viral load and adversarial clinical death outcomes or ARDS when compared with controlled cases from past. [19, 39] . Currently, WHO reject the further recovery trial and B. Cao et.al., have [53] reported that the lopinavir/ritonavir (n = 1596) intakes by hospitalized COVID-19 patients are not ending up with any kind of beneficial effects on comparison with the patients who received usual care (n = 3376).

Chloroquine, a quinoline derivative, was introduced into the field of drug and medicine in 1940s. It is an antimalarial agent. [54, 55] . It avoids virus-cell fusion by intruding with J o u r n a l P r e -p r o o f glycosylation of ACE2 receptor and on merging with spike protein it can impede the entry of nCoV-2. This mechanism of chloroquine suggests its efficiency as a therapeutic usage in initial stage of infection only. Hence, COVID-19 virus failed to get any chance to decrease the ACE2 activity and expression. But M. Borba et. al. [56] have also highlighted the side effects of the drug . According to the authors, high intakes of chloroquine i.e. total dose of 12 g or 600 mg twice daily for 10 days, may lead to cardiac infarction and should not be acclaimed for handling . Therefore, there are some safety and efficiency issues of these medications in preventing the virus of COVID-19.

Hydroxychloroquine (HCQ) falls into the class of medication of DMARD i.e. Disease-Modifying Anti-Rheumatic Drug. The drug is helpful in diminishing the pain and swelling in patients suffering from arthritis [57] . It was initially synthesized in India for the treatment of malaria. A latest study by Cochrane et al. [58] highlighted that this drug failed to give higher negative conversion rates, but its anti-inflammatory properties had decreased the symptoms and had helped in recovery of lymphopenia. However, UK Recovery trial and WHO Solidarity trial discontinued the usage of this drug in the month of June due to its failure in showing any clinical benefits in the COVID-19 patients [59, 60] .

LEAPS COVID-19 immunotherapy, known to diminish consequential lung damage and COVID-19 viral load, is directed by Cellular Immunology CEL-SCI Corporation using Ligand Epitope Antigen Presentation System (LEAPS) peptide technology(Source: CEL-SCI Corporation). Intravenous Immunoglobulin IV This immunotherapy got an acceptance from FDA in order to examine the safety in patients with the symptoms of COVID-19 and also to check its efficiency in the third phase trials. (Contemporary trials emphasizing on the complementary effects of low dose IVIG (0.5g/kg for 5 days, NCT04261426).

Antibody-based therapy is one viable treatment option targeting the immune system.

Here, for the therapeutic and prophylactic treatment of COVID-19, the active strategies have been discussed in an approach to develop neutralizing antibodies for the inhibition of SARS-CoV-2 [61] . leads to phagocytosis, cellular cytotoxicity, or direct counteraction of the pathogen [63, 64] . This therapy is purposeful for the people suffering from a cytokine storm or critical patients with meagre oxygen saturation levels. According to the ICMR protocol, people with severe risk of cytokine storm, pneumonitis in extreme case along with breathlessness are on priority for the therapy. It is an already used procedure for numerous diseases but the potency for SARS-CoV-2 is still not known and is under investigation [65] . (ClinicalTrials.gov Identifier: NCT04425915 and NCT04372979).

Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis which is now beneficial in combating the COVID-19 virus also. It is a humanized monoclonal antibody against the J o u r n a l P r e -p r o o f interleukin-6 receptor (IL-6R) calming that 'Cytokine Strom' may lower the risk of COVID-19 death [66, 67] . 

After the publication of the genetic sequencing of COVID-19 virus (SARS-CoV-2) on Jan 11, 2020, there was a rapid popping up of various studies and research, among the scientists with collaboration of researchers from biopharmaceutical industries, towards the production, 

According to the results recently obtained by Oxford's University research group [68, 69] , it is safe and successfully triggers an immune response against the coronavirus in human. The study showed that close to 90% of people developed neutralizing antibodies after consuming only one dose of the vaccine. There were no adverse side-effects of the vaccine. However, 70% of people on the trails developed either fever or headache, which could be managed with paracetamol.

Vaccine is considered as the world's most advanced candidate against COVID-19 in terms of development. infection [70] . A preliminary report submitted by L.A. Jackson et. al. [71] concluded that anti-SARS-CoV-2 immunity boosters were noted, using this vaccine, in all the targeted bodies and the identifications of concerns related to the trial's safety were not studied and reported. This phase clinical trial voluntarily. Now, Inovio is thinking for a beginning of a Phase II/III trial to examine the potency of the vaccine in the coming summer days. [73] Nanoparticle SARS-CoV-2 vaccine Novel nanoparticle vaccine technology based on a selfassembling nanoparticle could prove to be a game changer in the development of a COVID-19

vaccine. The development of this vaccine involves the use of self-assembling protein nanoparticle (1c-SapNP) vaccine technology. The nanoparticle vaccine would induce the immune system to rapidly generate antibodies to neutralize and deactivate the coronavirus, offering a recipient protection against the real SARS-CoV-2 virus [74] .

Biotech developed the inactivated vaccine against Covid-19. This was a purified but not activated virus vaccine candidate for SARS-CoV-2 virus named by "PiCoVacc" , produced by Qiang Gao and his team [75, 76] 

There are methodologies used for reprocessing the already existing medications and drugs. This technique of remodulating is responsible for the immunomodulators which are being successfully tested, in order to combat hyperinflammation caused by the release of cytokine .

that are under test and examination which might be useful in neutralizing the COVID-19 virus.

The purpose of interleukins, which fall in the category of cytokines, is hindered by IL-inhibitors. Macrophages, monocytes, lymphocytes, and few other cells are J o u r n a l P r e -p r o o f playing a major role in the synthesis of interleukin and are known as immunoregulators. IL inhibitors are immunosuppressant. Interleukin (IL) inhibitors such as tocilizumab [67] , sarilumab [78] , siltuximab [79] have been reported to improve the conditions of damaged lung tissues, caused by the deliverance of cytokine, in the COVID-19 infected patients.

A class of proteins, cytokine, is involved in generating the inflammatory responses which intervene with the immune system of the infected patient. Drugs such as Baricitinib, Ruxolitinib with kinases AAK1, and BIKE in complex that target JAK and NAK may attenuate the usual and alveolar inflammation in such pneumoniatic patients by inhibiting the actual process of the cytokines. [80] [81] [82] Statins: It has been reported by the scientists, M. Bifulco [83] and Vincenzo Castiglione [84] that HMG-CoA reductase inhibitors (statins), are benignant in diminishing the COVID-19 caused inflammations, due to their ability to lower down the inflammation caused by atherosclerosis. [101] , along with their cholesterol-lowering activity.

Corticosteroids: Corticosteroids find place in major recommendations of the European Society of Intensive Care Medicine. They are the inflammation-inhibiting drugs, with a contrasting safety profile in extreme infections caused by viral loads [85] . Corticosteroids are in strong recommendation for the patients on ventilation suffering with Acute Respiratory Distress Syndrome(ARDS), with Cytokine Storm Syndromes (CSS) and with the hemophagocytic lymphohistiocytosis syndromes (HLH)(ClinicalTrials.gov Identifier: NCT04273321).

CD24Fc: CD24Fc is a biological immunomodulatory response to tissue injuries which is believed to be involved in autoimmune disease, cancer, graft-versus-host disease (GvHD) and metabolic syndromes [86] . infection inside him [87, 88] . It is a type of corticosteroids, which imitates cortisol to some extent.

Cortisol is a hormone secreted by adrenal glands in human body. In the preliminary report [89] that is now also available in a pre-print server (Horby et al, medRxiv, June 22nd) and the UKbased RECOVERY,it is mentioned that the drug has minimized the death rates in the ventilated patients (up to by a third patient) and in the oxygen supported patients (up to by a fifth patients).

Some harmful effects of the drug has also been studied.

Multiple ongoing clinical studies are evaluating the use of vitamin and mineral supplements for both the treatment and prevention of SARS-CoV-2 infection [90, 91] . William B.

Grant et. al. [92] published a review on evidence that vitamin 'D' supplements are required for proper functioning of the immune system and reduces the threat of influenza and COVID-19.

Vitamin C shields the cells and tissues of a human body from dysfunction and oxidative damage, its ability to scavenge the impaired reactive oxygen species make it known to be the best antioxidant for the human body. [93, 94] . Recently, China has registered a new clinical trial (clincialtrials.gov Identifier: NCT04264533 & NCT04363216) to assess the action of vitamin C against a potential viral load of COVID-19. Zinc is a producer of WBC in the infected body and also known as an immune-booster. Due to its capability to minimize the replication of the virus, zinc is currently being examined for prevention and handling of COVID-19 cases [95, 96] .

Ayurveda, being the science of life, propagates the gifts of nature in maintaining healthy and happy living by improving the quality of standard care. Till now, there is no highly potential drug or medication in the market which can unroot the cause of the COVID-19 disease completely. In this critical times, it will be better to take ayurvedic medicines and preventive measures to boost immunity to stop the coronavirus from entering your body [97] [98] [99] . As per the report of WHO, around 80% population of the country is utilizing the herbal plants as the immunity-booster and to cure number of diseases. Various natural products produce important and useful ingredients like fennel, oregano oil, garlic, Echinacea, peppermint, sambucus, astragalus , licorice, ginger, turmeric, tulsi (ocimum tenuiflorum), etc. which contain different polyphenols, alkaloids, flavones, etc. These substances get involved into combating various viral J o u r n a l P r e -p r o o f loads and diseases as they generate interferons and antibodies in the infected or targeted person.

It increases the amount of phagocytosis, protecting agent from foreign unfavorable particles and also resists ACE2 to protect us from CoV-19 [100] [101] [102] [103] [104] .

The mechanisms of infection by the SARS-CoV2 are not clear yet, however, it is genetically similar to SARS-CoV and other coronaviruses [107] . Hence the common mode of pathogenicity is being explored for targets of treatment. The therapeutic targets depending on the common mode of pathogenicity can be classifed as virus-related targets and host-related targets. The mechanism of coronavirus entry and the working of vaccines against Covid-19 is shown in 

Sceintists have taken genes from different viruses or viral parts (spike protein, RNA) and put them into harmless virus to make a vaccine. Broadly, these vaccines can be categorized into three types such as protein-based, viral vector and mRNA-based vaccines. Protein-based vaccines: Virus's spike protein is purified and directly injected into body. Viral vector vaccines:

A virus such as measles or adenovirus is genetically engineered and injected. mRNA-based vaccines: mRNA that codes for spike protein is purified and injected.

When the vaccine is injected into the body, it provokes the immune system to produce antibodies It is also concluded that the reports and studies of the antivirals like lopinavir-ritonavir and remdesivir, which are already in the picture, are not that much effective and promising against SARS-CoV-2. A mild respiratory disease in the majority of cases have been marked in the case of COVID-19, but the studies of some cases have demonstrated that cytokine activation leads to sepsis and Acute Respiratory Distress Syndrome (ARDS) in the host cell, which may result to mortality and morbidity. An active exploration of biologics and treatments on the basis of immunomodulation, for the therapeutic usage in the COVID-19 cases has also been concluded here. Moreover, the severe effects by steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) has also been noticed and hence been discouraged to get into the use. It is in great hope that vaccines and specific medicaments targeting SARSCoV-2 will be in the world's health market in near future. J o u r n a l P r e -p r o o f

Host and viral traits predict zoonotic spillover from mammals

COVID-19: Emergence of Infectious Diseases

Human T-cell immunity against the emerging and re-emerging viruses

Global trends in emerging infectious diseases

SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview

Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or just like SARS

Emerging coronaviruses: First SARS, second MERS and third SARS-COV-2. epidemiological updates of COVID-19

Recent advances in the detection of respiratory virus infection in humans

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Viruses in bats and potential spillover to animals and humans

The novel zoonotic COVID-19 pandemic: An expected global health concern

Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic

Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19

Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

World Health Organization. Summary of probable SARS cases with onset of illness from 1

Clinical management and infection control of SARS: Lessons learned

Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings

Medical treatment of viral pneumonia including SARS in immunocompetent adult

Management of Critically Ill Patients with Severe Acute Respiratory Syndrome (SARS)

World Health Organization. MERS situation update

Middle East respiratory syndrome

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

World Health Organization, WHO Coronavirus Disease (COVID-19) Dashboard

Coronavirus disease 2019 (COVID-19): latest developments in potential treatments., Drugs Context

Drug targets for COVID-19 therapeutics: Ongoing global efforts

TITLE PAGE COVID-19 Treatment : Close to a Cure ? -A Rapid Review of Pharmacotherapies for the Novel Coronavirus Department of Pharmacy Services

A review of sars-cov-2 and the J o u r n a l P r e -p r o o f ongoing clinical trials

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Compassionate use of remdesivir for patients with severe Covid-19

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study

The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro

Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Ivermectin and COVID-19: Keeping rigor in times of urgency

Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2'-O-Methylation of Viral RNA

Aplidin (plitidepsin) is a novel anti-myeloma agent with J o u r n a l P r e -p r o o f potent anti-resorptive activity mediated by direct effects on osteoclasts

Vir and Alnylam Identify RNAi Therapeutic Development Candidate , VIR-2703 ( ALN-COV ), Targeting SARS-CoV-2 for the Treatment of COVID-19

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

New insights into the antiviral effects of chloroquine

The Benefits of Chloroquine Multi-Mechanisms of Action on the Nervous System

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb cl

Hydroxychloroquine and Covid-19: and Molecular Biology Based Update

Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19

Is hydroxychloroquine beneficial for COVID-19 patients?

Status of chloroquine and hydroxychloroquine in COVID-19 infection

Antibody therapies for the treatment of COVID-19

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

Treatment for emerging viruses: Convalescent plasma and COVID-19

Convalescent plasma as a potential therapy for COVID-19

Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1 / 2 , single-blind

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

An evidence based perspective on mRNA-SARScov-2 vaccine development

Beigel, mRNA-1273 Study Group, An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Immunogenicity of a DNA vaccine candidate for COVID-19

Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic

Title : Rapid development of an inactivated vaccine for SARS-CoV-2 Affiliation : Abstract

Development of an inactivated vaccine candidate for SARS-CoV-2, Science

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation : an open--label cohort study

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk

Inhibition as a New Treatment Strategy for Patients with COVID-19

Family-wide Structural Analysis of Human Numb-Associated Protein Kinases

Statin therapy in COVID-19 infection: much more than a single pathway

Statin therapy in COVID-19 infection

Fang Fang MD, Yingqi Xiao MN, Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys

Dexamethasone-induced immunosuppression: Mechanisms and implications for immunotherapy

Dexamethasone in the management of covid -19

Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

What is the role of supplementation with ascorbic acid , zinc , vitamin D , or N-acetylcysteine for prevention or treatment of COVID-19 ?

Covid-19: The inflammation link and the role of nutrition in potential mitigation

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

A new clinical trial to test high-dose vitamin C in patients with COVID-19

Vitamin C administration in the critically ill: A summary of recent metaanalyses

Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture

Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation

Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis

A narrative literature traditional medicine options for treatment of corona virus disease 2019 (COVID-19)

Identification of natural compounds with antiviral activities against SARS-associated coronavirus

Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines

Analysis on herbal medicines utilized for treatment of COVID-19

Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil

Time to realise the true potential of Ayurveda against COVID-19

Ayurvedic clinical profile of COVID-19 -A preliminary report

Coronavirus structure, mechanism of action, antiviral drug promises and rule out against it's treatment

Durg repurposing approach to fight covid-19

Preliminary identifca-tion of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies